Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

News • Focus on methylation changes

Detecting tumour DNA in urine to identify bladder cancer

Researchers from the University of Birmingham’s Bladder Cancer Research Centre have found a new way of detecting tumour DNA in urine to identify bladder cancer.

News • Biomaterial research

Parkinson's disease: hydrogel and acupuncture approach shows promise

A biodegradable, electroconductive self-healing hydrogel combined with acupuncture could help restore motor function and protect brain neurons in Parkinson’s disease models.

News • Research on Antrodia cinnamomea

Promising fungal compound to fight cancer and inflammation

Studies have found that natural polysaccharides from a medical fungus endemic to Taiwan can not only effectively inhibit inflammation, but also fight the proliferation of lung cancer cells.